CVT-124 data

CV Therapeutics said CVT-124 was safe and well-tolerated in a Phase I placebo-controlled, blinded, cross-over trial in 29 healthy volunteers. The dosages of the small molecule were 0.01, 0.03, 0.1 and 0.3 mg/kg, adminstered iv. Potential clinical utility was shown by statistically significant, dose-related increases in sodium and uric acid excretion, with only minimal loss of potassium.

The drug selectively blocks A1 receptors in the kidney, especially in the proximal tubule, which is responsible for most sodium reabsorption in CHF patients. This might make the drug useful in patients who have become unresponsive to distally-acting diuretics. ...